Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2001-10-10
pubmed:abstractText
Two cycles of high-dose chemotherapy with stem cell support (HDC) may increase the total dose delivered and dose intensity. A brief induction phase and different non-cross-resistant agents for each HDC cycle were used to avoid drug resistance. Twenty-six women with metastatic BC had induction and stem cell mobilization with two cycles of doxorubicin/G-CSF given every 14 days. Patients with stable disease or better after induction received HD CTCb followed by HD melphalan and dose-escalated paclitaxel. At 475 mg/m(2) of paclitaxel by 24-h infusion, dose-limiting transient peripheral sensory neuropathy was encountered. No toxic deaths occurred. Complete and near complete response after completion of therapy was achieved in 22 (85%) of 26 patients. The median EFS was 38 months. The median OS has not yet been reached. At a median follow-up of 33 (25-43) months, actuarial EFS and OS were 54% (95% confidence interval (CI), 39-69%) and 69% (95% CI, 56-79%), respectively. This double transplant approach lasts only 14 weeks and is feasible, safe, and tolerable. Whilst selection biases may in part contribute to favorable EFS and OS, a randomized comparison of standard therapy vs double transplant in both metastatic and locally advanced breast cancer is warranted.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
447-54
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:11593317-Adult, pubmed-meshheading:11593317-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11593317-Breast Neoplasms, pubmed-meshheading:11593317-Combined Modality Therapy, pubmed-meshheading:11593317-Disease-Free Survival, pubmed-meshheading:11593317-Doxorubicin, pubmed-meshheading:11593317-Drug Administration Schedule, pubmed-meshheading:11593317-Female, pubmed-meshheading:11593317-Follow-Up Studies, pubmed-meshheading:11593317-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11593317-Humans, pubmed-meshheading:11593317-Melphalan, pubmed-meshheading:11593317-Middle Aged, pubmed-meshheading:11593317-Neoplasm Metastasis, pubmed-meshheading:11593317-Neoplasm Recurrence, Local, pubmed-meshheading:11593317-Paclitaxel, pubmed-meshheading:11593317-Remission Induction, pubmed-meshheading:11593317-Survival Rate, pubmed-meshheading:11593317-Treatment Failure, pubmed-meshheading:11593317-Treatment Outcome
pubmed:year
2001
pubmed:articleTitle
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
pubmed:affiliation
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase II, Clinical Trial, Phase I